Physician profile
Thomas J Conti
NPI 1477648756
$713.50
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.12 · 2022: $108 · 2023: $242 · 2024: $203 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $179.06 | 2022-2023 | Tepezza |
| Amgen INC. | $147.82 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $78.67 | 2023-2024 | Cequa |
| Regeneron Healthcare Solutions, INC. | $63.05 | 2023-2024 | Eylea Hd, Eylea |
| Lkc Technologies, INC. | $45.97 | 2025 | |
| Bausch & Lomb Americas INC. | $43.52 | 2023 | Vyzulta, Miebo |
| Tarsus Pharmaceuticals, INC. | $33.68 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.12 | 2019 | |
| Sight Sciences, INC. | $18.52 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $18.10 | 2022 | |
| Genentech USA, INC. | $17.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.04 | 2022 | |
| Harrow Eye, LLC | $16.29 | 2024 | Vevye |
| Thea Pharma INC. | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Conti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.